Maintenance Therapy
INFORM; C-TONG 0805: A multicenter, double blind randomizedphase III trial of maintenance gefitinib compared to placebo inadvanced non-small cell lung cancer
Abstract
The standard first-line therapy for patients with locally
advanced or metastatic non-small cell lung cancer
(NSCLC) is platinum-based chemotherapy (1). With
standard first line platinum-based therapy approximately
75% of patients will obtain disease control, the median
progression-free survival (PFS) is 4-6 months, and median
overall survival (OS) is 10-13 months (2-5). Phase III trials
that investigated a longer duration compared to a shorter
duration of platinum-based therapy failed to reveal an
improvement in OS with the longer duration of therapy
(6-9).
advanced or metastatic non-small cell lung cancer
(NSCLC) is platinum-based chemotherapy (1). With
standard first line platinum-based therapy approximately
75% of patients will obtain disease control, the median
progression-free survival (PFS) is 4-6 months, and median
overall survival (OS) is 10-13 months (2-5). Phase III trials
that investigated a longer duration compared to a shorter
duration of platinum-based therapy failed to reveal an
improvement in OS with the longer duration of therapy
(6-9).
